Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -562.43 Million CNY | -16.93% |
| 2022 | -481.02 Million CNY | -31.87% |
| 2021 | -364.76 Million CNY | -159.48% |
| 2020 | 613.24 Million CNY | -24.31% |
| 2019 | 810.23 Million CNY | 42.94% |
| 2018 | 566.84 Million CNY | 65.72% |
| 2017 | 342.05 Million CNY | -1.68% |
| 2016 | 347.88 Million CNY | 93.81% |
| 2015 | 179.49 Million CNY | -71.1% |
| 2014 | 621.2 Million CNY | 382.44% |
| 2013 | 128.76 Million CNY | -39.03% |
| 2012 | 211.19 Million CNY | 31.42% |
| 2011 | 160.69 Million CNY | 362.23% |
| 2010 | -61.28 Million CNY | 82.1% |
| 2009 | -342.44 Million CNY | -1997.0% |
| 2008 | 18.05 Million CNY | 697.72% |
| 2007 | -3.02 Million CNY | -113.4% |
| 2006 | 22.53 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -636.58 Million CNY | -13.18% |
| 2024 Q2 | -658.76 Million CNY | -3.48% |
| 2024 Q3 | -801.02 Million CNY | -20.9% |
| 2023 Q1 | -533.92 Million CNY | -11.0% |
| 2023 FY | -562.43 Million CNY | -16.93% |
| 2023 Q4 | -562.43 Million CNY | -5.16% |
| 2023 Q3 | -534.83 Million CNY | -6.09% |
| 2023 Q2 | -504.15 Million CNY | 5.58% |
| 2022 FY | -481.02 Million CNY | -31.87% |
| 2022 Q1 | -307.4 Million CNY | 15.73% |
| 2022 Q4 | -481.02 Million CNY | -36.07% |
| 2022 Q2 | -295.65 Million CNY | 3.82% |
| 2022 Q3 | -353.51 Million CNY | -19.57% |
| 2021 Q3 | -411.46 Million CNY | 7.05% |
| 2021 Q4 | -364.76 Million CNY | 11.35% |
| 2021 Q2 | -442.65 Million CNY | 19.69% |
| 2021 FY | -364.76 Million CNY | -159.48% |
| 2021 Q1 | -551.19 Million CNY | -189.88% |
| 2020 Q1 | 828.62 Million CNY | 2.27% |
| 2020 FY | 613.24 Million CNY | -24.31% |
| 2020 Q2 | 755.5 Million CNY | -8.82% |
| 2020 Q3 | 588.11 Million CNY | -22.16% |
| 2020 Q4 | 613.24 Million CNY | 4.27% |
| 2019 Q1 | 550.27 Million CNY | -2.92% |
| 2019 FY | 810.23 Million CNY | 42.94% |
| 2019 Q2 | 769.21 Million CNY | 39.79% |
| 2019 Q4 | 810.23 Million CNY | -1.87% |
| 2019 Q3 | 825.71 Million CNY | 7.35% |
| 2018 Q4 | 566.84 Million CNY | -19.87% |
| 2018 FY | 566.84 Million CNY | 65.72% |
| 2018 Q3 | 707.38 Million CNY | 38.13% |
| 2018 Q2 | 512.11 Million CNY | 17.22% |
| 2018 Q1 | 436.88 Million CNY | 27.72% |
| 2017 Q2 | 383.66 Million CNY | 4.87% |
| 2017 Q1 | 365.84 Million CNY | 5.16% |
| 2017 Q3 | 248.7 Million CNY | -35.18% |
| 2017 Q4 | 342.05 Million CNY | 37.53% |
| 2017 FY | 342.05 Million CNY | -1.68% |
| 2016 Q4 | 347.88 Million CNY | -13.91% |
| 2016 Q3 | 404.09 Million CNY | 43.11% |
| 2016 Q2 | 282.36 Million CNY | 44.15% |
| 2016 Q1 | 195.88 Million CNY | 9.13% |
| 2016 FY | 347.88 Million CNY | 93.81% |
| 2015 Q2 | 738.68 Million CNY | 7.83% |
| 2015 Q4 | 179.49 Million CNY | -75.08% |
| 2015 FY | 179.49 Million CNY | -71.1% |
| 2015 Q3 | 720.43 Million CNY | -2.47% |
| 2015 Q1 | 685.03 Million CNY | 10.28% |
| 2014 Q2 | 351.82 Million CNY | 45.68% |
| 2014 FY | 621.2 Million CNY | 382.44% |
| 2014 Q1 | 241.5 Million CNY | 87.56% |
| 2014 Q3 | 536.76 Million CNY | 52.56% |
| 2014 Q4 | 621.2 Million CNY | 15.73% |
| 2013 Q1 | -39.53 Million CNY | -118.72% |
| 2013 Q2 | 99.96 Million CNY | 352.84% |
| 2013 FY | 128.76 Million CNY | -39.03% |
| 2013 Q3 | 56.91 Million CNY | -43.06% |
| 2013 Q4 | 128.76 Million CNY | 126.23% |
| 2012 Q3 | 158.3 Million CNY | 138.23% |
| 2012 Q4 | 211.19 Million CNY | 33.41% |
| 2012 Q2 | 66.45 Million CNY | -71.72% |
| 2012 FY | 211.19 Million CNY | 31.42% |
| 2012 Q1 | 234.98 Million CNY | 46.23% |
| 2011 Q2 | 91.41 Million CNY | 715.04% |
| 2011 FY | 160.69 Million CNY | 362.23% |
| 2011 Q4 | 160.69 Million CNY | -6.94% |
| 2011 Q3 | 172.67 Million CNY | 88.89% |
| 2011 Q1 | 11.21 Million CNY | 118.3% |
| 2010 Q1 | -302.09 Million CNY | 11.78% |
| 2010 Q4 | -61.28 Million CNY | 73.28% |
| 2010 FY | -61.28 Million CNY | 82.1% |
| 2010 Q3 | -229.38 Million CNY | 6.5% |
| 2010 Q2 | -245.33 Million CNY | 18.79% |
| 2009 Q2 | 21.84 Million CNY | 0.0% |
| 2009 FY | -342.44 Million CNY | -1997.0% |
| 2009 Q4 | -342.44 Million CNY | 1.28% |
| 2009 Q3 | -346.89 Million CNY | -1688.15% |
| 2008 Q4 | 18.05 Million CNY | 0.0% |
| 2008 FY | 18.05 Million CNY | 697.72% |
| 2007 FY | -3.02 Million CNY | -113.4% |
| 2006 FY | 22.53 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 935.92 Million CNY | 160.094% |
| Zhejiang Zhenyuan Share Co., Ltd. | -320.75 Million CNY | -75.346% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | 580.71 Million CNY | 196.853% |
| Hubei Guangji Pharmaceutical Co., Ltd. | 520.61 Million CNY | 208.033% |
| Yifan Pharmaceutical Co., Ltd. | 1.29 Billion CNY | 143.37% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | -129.14 Million CNY | -335.522% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 2.88 Billion CNY | 119.526% |
| Boai NKY Medical Holdings Ltd. | -230.36 Million CNY | -144.149% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | -1.1 Billion CNY | 49.281% |